Systematic analysis of CD39, CD103, CD137, and PD‐1 as biomarkers for naturally occurring tumor antigen‐specific TILs
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Systematic analysis of CD39, CD103, CD137, and PD‐1 as biomarkers for naturally occurring tumor antigen‐specific TILs
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF IMMUNOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2021-09-10
DOI
10.1002/eji.202149329
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- FS222, a CD137/PD-L1 tetravalent bispecific antibody exhibits low toxicity and anti-tumor activity in colorectal cancer models
- (2020) Matthew A Lakins et al. CLINICAL CANCER RESEARCH
- Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study
- (2020) Dmitriy Zamarin et al. JOURNAL OF CLINICAL ONCOLOGY
- CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement
- (2020) Miguel Gaspar et al. Cancer Immunology Research
- PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
- (2019) Takahiro Kamada et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Adoptive Immunotherapy with Antigen-Specific T Cells Expressing a Native TCR
- (2019) Wingchi Leung et al. Cancer Immunology Research
- Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
- (2019) Andrea Cossarizza et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- T Cell Dysfunction in Cancer
- (2018) Daniela S. Thommen et al. CANCER CELL
- Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer
- (2018) Neil H. Segal et al. CLINICAL CANCER RESEARCH
- Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells
- (2018) Bertram Bengsch et al. IMMUNITY
- Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors
- (2018) Thomas Duhen et al. Nature Communications
- Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients
- (2017) Alice O. Kamphorst et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
- (2017) Alice O. Kamphorst et al. SCIENCE
- Selection of Shared and Neoantigen-Reactive T Cells for Adoptive Cell Therapy Based on CD137 Separation
- (2017) Sivan Seliktar-Ofir et al. Frontiers in Immunology
- PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?
- (2017) Sylvain Simon et al. OncoImmunology
- Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
- (2016) Neil H. Segal et al. CLINICAL CANCER RESEARCH
- Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression
- (2016) Maria Parkhurst et al. CLINICAL CANCER RESEARCH
- Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis
- (2015) Jacob H. Levine et al. CELL
- Prognostic Role of Tumor-Infiltrating Lymphocytes in Lung Cancer: a Meta-Analysis
- (2015) Yiting Geng et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- CD8+CD103+Tumor–Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients
- (2015) Fayçal Djenidi et al. JOURNAL OF IMMUNOLOGY
- Immune Checkpoint Inhibition: Therapeutic Implications in Epithelial Ovarian Cancer
- (2015) Teresa Longoria et al. Recent Patents on Anti-Cancer Drug Discovery
- Overcoming T cell exhaustion in infection and cancer
- (2015) Kristen E. Pauken et al. TRENDS IN IMMUNOLOGY
- PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
- (2014) Alena Gros et al. JOURNAL OF CLINICAL INVESTIGATION
- Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
- (2014) E. Tran et al. SCIENCE
- CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor
- (2013) Q. Ye et al. CLINICAL CANCER RESEARCH
- viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia
- (2013) El-ad David Amir et al. NATURE BIOTECHNOLOGY
- Co-Stimulation through 4-1BB/CD137 Improves the Expansion and Function of CD8+ Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell Therapy
- (2013) Jessica Ann Chacon et al. PLoS One
- Tumor-specific CD4+ Melanoma Tumor-infiltrating Lymphocytes
- (2012) Kevin M. Friedman et al. JOURNAL OF IMMUNOTHERAPY
- Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1
- (2008) Naomi N. Hunder et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now